Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repurposing of Chlorpromazine in Covid-19 Treatment (reCoVery)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04366739
Recruitment Status : Not yet recruiting
First Posted : April 29, 2020
Last Update Posted : April 29, 2020
Sponsor:
Collaborator:
Hôpital Cochin
Information provided by (Responsible Party):
Centre Hospitalier St Anne

Brief Summary:
This study evaluates the effects of the addition of chlorpromazine to the standard therapeutic protocol in COVID-19 patients hospitalized for respiratory symptom management (score 3-5 WHO Ordinal Scale for Clinical Improvement).

Condition or disease Intervention/treatment Phase
COVID-19 Drug: CHLORPROMAZINE (CPZ) Combination Product: Standard of Care (SOC) Phase 3

Detailed Description:

This study evaluates the effects of the addition of chlorpromazine to the standard therapeutic protocol in COVID 19 patients hospitalized for respiratory symptom management (score 3-5 WHO Ordinal Scale for Clinical Improvement).

The investigators have observed in GHU-Paris psychiatry Hospital units (140 beds), significantly lower prevalence of symptomatic and severe forms of COVID-19 in patients (3%) than in the health workers operating in the same facilities (19% of nurses and 18% of physicians). COVID-psychiatry units report similar feedback in France, Spain, and Italy. One hypothesis could be that psychotropic drugs have a protective action on COVID-19 and protect patients from symptomatic and virulent forms of COVID-19.

This hypothesis is consistent with research studies that have shown that several psychotropic drugs inhibit in vitro viral replication of the coronaviruses MERS-CoV and SARS-CoV-1. The SARS-CoV-2 has many characteristics in common with the coronavirus family and has phylogenetic similarities to the SARS-CoV-1 engaged in the 2002-2003 outbreak. It is, therefore, possible that one or more psychotropic drugs having demonstrated efficacy against MERS-CoV and SARS-CoV-1 also have anti-SARS-CoV-2 antiviral activity.

The current global epidemic of COVID-19, with a high number of deaths in many countries, makes it urgent to search drugs potentially useful to reduce the severity and lethality of the infection. Drug repositioning represents a possible alternative to the news medicines discovery. This strategy makes it possible to eliminate many stages of development; it makes it possible to deploy a therapy whose side effects are known and which physicians already well know how to handle.

To confirm the hypothesis of the antiviral action of chlorpromazine on SARS-CoV-2, a preclinical in vitro experiment began in April 2020 at the level III high-security biological laboratory at the Pasteur Institute (in collaboration with the GHU PARIS Psychiatry & Neurosciences). The first results are encouraging and show a marked antiviral effect of chlorpromazine on SARS-CoV-2. Technical replicas are underway to validate these preliminary results.

By integrating all these evidence, the investigators hypothesize that chlorpromazine could decrease the unfavorable evolution of COVID-19 infection when administered at the onset of respiratory signs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Allocation: Randomized Intervention Model: Parallel Assignment

Intervention Model Description:

reCoVery is a multi-center, randomized, single-blind, standard care-controlled (1:1) pilot clinical study to explore the efficacy and safety of chlorpromazine (CPZ) in the treatment of adult subjects with COVID-19-moderate type (WHO-OSCI 3-5).

Masking: Single (Outcomes Assessor)
Masking Description:

The evaluator of the primary endpoint and secondary endpoints relating to the clinical efficacy of CPZ and the evaluator of the biological and radiological effects of the CPZ will be maintained blindly throughout their duration of inclusion. This evaluator will collect clinical data, biological data, and imaging data without knowing the drug treatments delivered to patients.

The radiologists responsible for calculating the parenchymal damage score on the thoracic CT scan will be blind to the patient delivered drugs.

The biologists responsible for carrying out the analyzes on the biobank will be blind to the patient delivered drugs.

The biostatistician responsible for statistical study analysis will be kept blind to the drugs delivered to the subjects.

Primary Purpose: Treatment
Official Title: Repurposing of Chlorpromazine in Covid-19 Treatment
Estimated Study Start Date : April 29, 2020
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CHLORPROMAZINE (CPZ)
Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
Drug: CHLORPROMAZINE (CPZ)

Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.

Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).

Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.

Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum


Combination Product: Standard of Care (SOC)
In the absence of a reference treatment in COVID-19, the "standard of care" (SOC) is the comparison arm

Active Comparator: standard of care (SOC)
In the absence of a reference treatment in COVID-19, the "standard of care" (SOC) is the comparator arm
Combination Product: Standard of Care (SOC)
In the absence of a reference treatment in COVID-19, the "standard of care" (SOC) is the comparison arm




Primary Outcome Measures :
  1. Time To Response (TTR) [ Time Frame: 28 days ]

    The primary endpoint is the time to response (TTR) in days, from randomization to 28th day. By response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI)

    The WHO-OSCI is an ordinal scale of 9 severity levels (from 0 to 8) for COVID-19. This scale was established by the WHO, which recommends its use for any therapeutic study on COVID-19.

    This will be a continuous outcome defined by the amount of time between randomization to the first response. This will be treated as a time-to-event with possible censoring.



Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 28 days from randomization ]

    Response rate regarding the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI).

    This will be a binary outcome defined by clinical conditions improvement assessment from randomization to 28th Day, by the response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI).


  2. All-cause mortality [ Time Frame: 28 days after randomization ]
    All-cause mortality rates at Day 28th after randomization

  3. Duration in days required for hospital discharge [ Time Frame: 28 days after randomization ]
    This will be a continuous outcome defined by the amount of time in days between randomization and the hospital discharge

  4. Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours [ Time Frame: 28 days after randomization ]

    This will be a continuous outcome defined by the amount of time in days between randomization and National Early Warning Score ≤ 2 maintained for almost 24 hours

    The National Early Warning Score (NEWS) is a score used in the ICU to evaluate the overall severity of the clinical condition of a patient.


  5. Number of days without oxygen therapy [ Time Frame: 28 days after randomization ]
    This will be a continuous outcome defined by the amount of time in days without oxygen therapy

  6. Incidence of oxygen use, NIV or high flow oxygen therapy [ Time Frame: 28 days after randomization ]
    Number of clinical conditions that need a prescription for Oxygen therapy, NIV or high flow oxygen therapy

  7. Duration in days of oxygen prescription, NIV or high flow oxygen therapy [ Time Frame: 28 days after randomization ]
    This will be a continuous outcome defined by the amount of time in days with oxygen therapy, NIV, or high flow oxygen therapy.

  8. Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample [ Time Frame: day 7 from randomization ]
    Rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample (biobank sample) (day 7) This will be a binary outcome defined by positive or negative results at SARS-CoV-2 PCR on a nasopharyngeal sample

  9. Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample [ Time Frame: day 7 from randomization ]
    This will be a quantitative variable. Biobank sample at day 7

  10. Biochemical response: serum viral load of SARS-CoV-2 [ Time Frame: day: 3,5,7,14,21,28 ]
    This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  11. Biochemical response: C-reactive protein (CRP) [ Time Frame: day: 3,5,7,14,21,28 ]
    This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  12. Biochemical response: blood test for lymphocytes (lymphopenia) [ Time Frame: day: 3,5,7,14,21,28 ]
    This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  13. Parenchymal involvement (chest CT) [ Time Frame: day 7 ]
    Extension score of parenchymal involvement in thoracic computed tomography (CT) (D7)

  14. Define the optimal dose of CPZ and its tolerance: rates of serious adverse events [ Time Frame: 28 days ]
    Rates of serious adverse events

  15. Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects [ Time Frame: 28 days ]
    Rates of non-serious side effects

  16. Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS) [ Time Frame: 28 days ]

    Global Anxiety - Visual Analog Scale (GA-VAS) is a scale for the assessment of anxiety. The 100 mm GA-VAS varies from minimum (not at all anxious) to maximum (Extremely anxious).

    This will be a quantitative variable, the distance from the left edge of the line to the mark placed by the patient is measured to the nearest millimeter and used in analyses as the patient's GA-VAS score.


  17. Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation [ Time Frame: 28 days ]
    Rates of drug discontinuation in all causes under study

  18. Define the optimal dose of CPZ and its tolerance: biological anomalies [ Time Frame: day: 3,5,7,14,21,28 ]
    NFS, TP TCA, blood ionogram and hepatic check-up, glycemia. This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  19. Define the optimal dose of CPZ and its tolerance: ECG abnormalities [ Time Frame: day: 3,5,7,14,21,28 ]
    Rate of patients with ECG abnormalities at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  20. Define the optimal dose of CPZ and its tolerance: plasma CPK assessment [ Time Frame: day: 3,5,7,14,21,28 ]
    plasma CPK assessment at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  21. Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment [ Time Frame: day: 3,5,7,14,21,28 ]
    Plasma CPZ assessment at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28

  22. Define the optimal dose of CPZ and its tolerance: CPZ dose administered [ Time Frame: 28 days ]
    CPZ dosages administered


Other Outcome Measures:
  1. Evaluate the biological parameters to treatment response (biobank constitution for carrying out cytokine assays, lymphocyte profiles in flow cytometry and additional explorations according to the evolution of knowledge on COVID-19) [ Time Frame: day: 1, 3,5,7,14,21,28 ]
    Biobank by blood samples of 20 ml per patient (on D1, D3, D5, D7, then, if continued hospitalization at D14, D21, D28) allowing, in addition to viral markers:Cytokine and lymphocyte profile assays in flow cytometry: IL-2, IL-6, IL-7, IL-10, GCSF, IP10, MCP1, M1P1A and TNF-alfa, FACs CD3, CD4, CD8, CD38



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biological and/or radiological diagnosis of COVID-19 infection
  • WHO-OSCI at 3, 4 or 5 at the time of inclusion
  • Benefiting from a social security scheme
  • Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures

Exclusion Criteria:

  • Treatment with chlorpromazine (CPZ) the month preceding the inclusion visit
  • Contraindication to the CPZ:
  • Hypersensitivity to the active substance or any of the excipients
  • Risk of glaucoma by closing the angle.
  • Risk of urinary retention linked to urethroprostatic disorders.
  • History of agranulocytosis
  • Association with dopaminergic outside Parkinson's (cabergoline, quinagolide), citalopram, escitalopram, domperidone, hydroxyzine, and piperaquine
  • Wheat allergy
  • Risk of QT prolongation and occurrence of severe ventricular rhythm disorders: the existence of bradycardia, hypokalaemia, long congenital or acquired QT
  • History of ischemic stroke
  • Treatment with chloroquine or hydroxychloroquine during the inclusion visit or the previous month
  • Need for mechanical ventilation linked to COVID-19, during the inclusion visit or the last month
  • In the opinion of the clinical team, imminent progression to death within the next 24 hours regardless of treatment
  • Psychiatric care under duress
  • Protected adults, persons under the protection of justice
  • Pregnant or lactating woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04366739


Contacts
Layout table for location contacts
Contact: Marion Plaze, MD, PHD 0145658646 ext 0033 m.plaze@ghu-paris.fr
Contact: Raphaël Gaillard, MD, PHD 0145658646 ext 0033 r.gaillard@ghu-paris.fr

Locations
Layout table for location information
France
Centre Hospitalier Sainte-Anne
Paris, France, 75014
Contact: Marion Plaze, MD, PHD    0145658652 ext 0033    m.plaze@ghu-paris.fr   
Contact: Raphaël Gaillard, MD, PHD    0145658652 ext 0033    r.gaillard@ghu-paris.fr   
Sponsors and Collaborators
Centre Hospitalier St Anne
Hôpital Cochin
Investigators
Layout table for investigator information
Principal Investigator: Marion Plaze, MD, PHD Service Hospitalo-Universitaire - GHU PARIS Psychiatrie & Neurosciences
Publications:

Layout table for additonal information
Responsible Party: Centre Hospitalier St Anne
ClinicalTrials.gov Identifier: NCT04366739    
Other Study ID Numbers: D20-P016
First Posted: April 29, 2020    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier St Anne:
COVID-19
Chlorpromazine
Additional relevant MeSH terms:
Layout table for MeSH terms
Chlorpromazine
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action